Dionex is pleased to announce the release of Application Update 178: Faster Solution with Increased Resolution for Determining Chromatographic Identity and Absence of OSCS in Heparin Sodium. The U.S. Pharmacopeia Monograph for Heparin Sodium was revised after oversulfated chondroitin sulfate (OSCS)-contaminated heparin led to the deaths of over 100 patients.

The method demonstrated in AU 178 achieves better resolution of heparin, dermatan sulfate, and OSCS using the higher-capacity Dionex IonPac® AS11-HC column, instead of the L61 column (e.g., IonPac AS11 column) specified in the monograph. In addition to improved resolution, the method is significantly faster, and it replaces the sodium perchlorate eluent with a more environmentallyfriendly sodium chloride eluent.

For more information, visit www.dionex.com or contact your local Dionex representative.

Dionex (NASDAQ:DNEX) is a global leader in the manufacturing and marketing of liquid chromatography and sample preparation systems, consumables, and software for chemical analysis. The company's systems are used worldwide in environmental analysis and by the life sciences, chemical, petrochemical, food and beverage, power generation, and electronics industries. Our expertise in applications and instrumentation helps analytical scientists to evaluate and develop pharmaceuticals, establish environmental regulations, and produce better industrial products.

IonPac is a registered trademark of Dionex Corporation.